Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 8/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8947154 | 0.88 | CHRNB2 (0.60) | PDCD1CD274CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL436284 | 0.87 | KEAP1 (0.57) | PDCD1CD274CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL449968 | 0.82 | HDAC3 (0.51) | PDCD1CD274MAPK1 | |
| SCHEMBL30402499 | 0.79 | SUCNR1 (0.51) | PDCD1CD274CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL28254835 | 0.79 | SUCNR1 (0.51) | PDCD1CD274CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL7697059 | 0.79 | CHRNB2 (0.56) | PDCD1CD274CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL436252 | 0.78 | KMT2A (0.44) | MAPK1MEN1KMT2AKDM4EGAA | |
| SCHEMBL5533081 | 0.77 | PDCD1 (0.60) | PDCD1CD274MEN1KMT2A | |
| SCHEMBL29256186 | 0.77 | HDAC7 (0.59) | PDCD1CD274CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL29918042 | 0.77 | PDCD1 (0.60) | PDCD1CD274MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716326-B2 | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-05-06 | — | — | US | disclosed |
| US-20120065396-A1 | ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065396-A1 | ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME | PPIP5K2, SOST, ALPL | PDCD1 746/4885CD274 2842/4885CHRNB2 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.